Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis

SIMPLE SUMMARY: High-risk neuroblastoma accounts for 4% of newly diagnosed pediatric malignancies, but for 9–10% of pediatric cancer mortality. To reduce the number of (late) recurrences and subsequently improve survival, anti-GD2 monoclonal antibody based immunotherapy has been added to the mainten...

Descripción completa

Detalles Bibliográficos
Autores principales: Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K. A., van Grotel, Martine, Kraal, Kathelijne C. J. M., Peek, Annemarie M. L., Tytgat, Godelieve A. M., van Noesel, Max M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507806/
https://www.ncbi.nlm.nih.gov/pubmed/34638426
http://dx.doi.org/10.3390/cancers13194941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507806/
https://www.ncbi.nlm.nih.gov/pubmed/34638426
http://dx.doi.org/10.3390/cancers13194941

Ejemplares similares